Rajesh Chopra
YOU?
Author Swipe
View article: Bilateral knee synovial chondromatosis with osteoarthritis - A case report
Bilateral knee synovial chondromatosis with osteoarthritis - A case report Open
View article: Evaluation of Combined Use of Pre-contoured Locking Distal Clavicle Plate and Tunneled Suspensory Device Fixation for Unstable Lateral End Clavicle Fracture
Evaluation of Combined Use of Pre-contoured Locking Distal Clavicle Plate and Tunneled Suspensory Device Fixation for Unstable Lateral End Clavicle Fracture Open
Introduction: Unstable lateral end clavicle fractures (Neer type 2) are prone to non-union due to various deforming forces and present a challenge in management. While multiple fixation techniques exist, each has its own complications. Com…
View article: 1470 START001: a phase 1/2 study of invikafusp alfa (STAR0602), a first-in-class TCR β chain-targeted bispecific antibody, as monotherapy in patients with antigen-rich solid tumors resistant to anti-PD(L)1
1470 START001: a phase 1/2 study of invikafusp alfa (STAR0602), a first-in-class TCR β chain-targeted bispecific antibody, as monotherapy in patients with antigen-rich solid tumors resistant to anti-PD(L)1 Open
View article: Diagnostic Value of Fiberoptic Bronchoscopy in Non-resolving Pneumonia: Case Series and Implications
Diagnostic Value of Fiberoptic Bronchoscopy in Non-resolving Pneumonia: Case Series and Implications Open
Non-resolving or slowly resolving pneumonia presents a significant diagnostic challenge, characterized by persistent radiographic abnormalities despite appropriate antibiotic therapy. This study explores the pivotal role of Fiberoptic Bron…
View article: A Rare Tumorous Presentation of Endobronchial Tuberculosis: Clinical Insights and Case Analysis
A Rare Tumorous Presentation of Endobronchial Tuberculosis: Clinical Insights and Case Analysis Open
Endobronchial tuberculosis (EBTB) is a rare manifestation of pulmonary tuberculosis characterized by bronchial inflammation, often presenting with tumor-like masses in the airways. Misdiagnosis, particularly as lung cancer or bronchial ast…
View article: iTAG an optimized IMiD-induced degron for targeted protein degradation in human and murine cells
iTAG an optimized IMiD-induced degron for targeted protein degradation in human and murine cells Open
View article: Time to Look for Ergonomically Viable Designs of Radiation Protection Aprons and Thyroid Shields in Orthopedic Surgery: A Survey of 416 Orthopedic Surgeons
Time to Look for Ergonomically Viable Designs of Radiation Protection Aprons and Thyroid Shields in Orthopedic Surgery: A Survey of 416 Orthopedic Surgeons Open
View article: Front Cover: A Degron Blocking Strategy Towards Improved CRL4<sup>CRBN</sup> Recruiting PROTAC Selectivity (ChemBioChem 23/2023)
Front Cover: A Degron Blocking Strategy Towards Improved CRL4<sup>CRBN</sup> Recruiting PROTAC Selectivity (ChemBioChem 23/2023) Open
E3 ligase mediated targeted protein degradation is an ever more important area in drug discovery. In the case of cereblon two avenues exist; either heterobifunctional PROTACs, or discrete cereblon ligands that induce a specific neosubstrat…
View article: Evaluation of early functional outcome of arthroscopic decompression in chronic primary sub-acromial impingement syndrome
Evaluation of early functional outcome of arthroscopic decompression in chronic primary sub-acromial impingement syndrome Open
Background: Sub-Acromial Impingement Syndrome (SAIS) spectrum ranges from acute inflammation to chronic degeneration of the bursa and of rotator cuff tendons in sub-acromial space. It may lead to a full-thickness tear of rotator cuf…
View article: A Degron Blocking Strategy Towards Improved CRL4<sup>CRBN</sup> Recruiting PROTAC Selectivity**
A Degron Blocking Strategy Towards Improved CRL4<sup>CRBN</sup> Recruiting PROTAC Selectivity** Open
Small molecules inducing protein degradation are important pharmacological tools to interrogate complex biology and are rapidly translating into clinical agents. However, to fully realise the potential of these molecules, selectivity remai…
View article: Evaluation of the functional outcome following endoscopic decompression of retrocalcaneal bursitis
Evaluation of the functional outcome following endoscopic decompression of retrocalcaneal bursitis Open
Introduction: Retro calcaneal bursitis is an inflammation of the bursa located between the posterior surface of the heel bone and the anterior surface of the Achilles tendon. This study was conducted to evaluate the clinical efficac…
View article: iTAG an optimized IMiD-induced degron for targeted protein degradation in human and murine cells
iTAG an optimized IMiD-induced degron for targeted protein degradation in human and murine cells Open
View article: Supplementary Figure Legends from Genetic and Pharmacologic Evidence That mTOR Targeting Outweighs mTORC1 Inhibition as an Antimyeloma Strategy
Supplementary Figure Legends from Genetic and Pharmacologic Evidence That mTOR Targeting Outweighs mTORC1 Inhibition as an Antimyeloma Strategy Open
PDF file - 29K
View article: Supplementary Figure Legends from Genetic and Pharmacologic Evidence That mTOR Targeting Outweighs mTORC1 Inhibition as an Antimyeloma Strategy
Supplementary Figure Legends from Genetic and Pharmacologic Evidence That mTOR Targeting Outweighs mTORC1 Inhibition as an Antimyeloma Strategy Open
PDF file - 29K
View article: Data from Genetic and Pharmacologic Evidence That mTOR Targeting Outweighs mTORC1 Inhibition as an Antimyeloma Strategy
Data from Genetic and Pharmacologic Evidence That mTOR Targeting Outweighs mTORC1 Inhibition as an Antimyeloma Strategy Open
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates cell growth, proliferation, metabolism, and cell survival, and plays those roles by forming two functionally distinct multiprotein complexes: mTOR complex…
View article: Supplementary Figure 1 from Genetic and Pharmacologic Evidence That mTOR Targeting Outweighs mTORC1 Inhibition as an Antimyeloma Strategy
Supplementary Figure 1 from Genetic and Pharmacologic Evidence That mTOR Targeting Outweighs mTORC1 Inhibition as an Antimyeloma Strategy Open
PDF file - 64K, Supplementary Figure 1. Detection of phospho-proteins in myeloma patient cells.
View article: Data from Genetic and Pharmacologic Evidence That mTOR Targeting Outweighs mTORC1 Inhibition as an Antimyeloma Strategy
Data from Genetic and Pharmacologic Evidence That mTOR Targeting Outweighs mTORC1 Inhibition as an Antimyeloma Strategy Open
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates cell growth, proliferation, metabolism, and cell survival, and plays those roles by forming two functionally distinct multiprotein complexes: mTOR complex…
View article: Supplementary Figure 1 from Genetic and Pharmacologic Evidence That mTOR Targeting Outweighs mTORC1 Inhibition as an Antimyeloma Strategy
Supplementary Figure 1 from Genetic and Pharmacologic Evidence That mTOR Targeting Outweighs mTORC1 Inhibition as an Antimyeloma Strategy Open
PDF file - 64K, Supplementary Figure 1. Detection of phospho-proteins in myeloma patient cells.
View article: Supplementary Figure 3 from The mTOR Kinase Inhibitors, CC214-1 and CC214-2, Preferentially Block the Growth of EGFRvIII-Activated Glioblastomas
Supplementary Figure 3 from The mTOR Kinase Inhibitors, CC214-1 and CC214-2, Preferentially Block the Growth of EGFRvIII-Activated Glioblastomas Open
PDF file - 1554K, Cap-dependent translation is enhanced by EGFRvIII expression and CC214-1 strongly inhibits P-4E-BP1 phosphorylation.
View article: Data from A First-in-Human Study of Novel Cereblon Modulator Avadomide (CC-122) in Advanced Malignancies
Data from A First-in-Human Study of Novel Cereblon Modulator Avadomide (CC-122) in Advanced Malignancies Open
Purpose:Avadomide is a novel, small-molecule therapeutic agent that modulates cereblon E3 ligase activity and exhibits potent antitumor and immunomodulatory activities. This first-in-human phase I study (NCT01421524) evaluated the safety a…
View article: Supplementary Figure 2 from The mTOR Kinase Inhibitors, CC214-1 and CC214-2, Preferentially Block the Growth of EGFRvIII-Activated Glioblastomas
Supplementary Figure 2 from The mTOR Kinase Inhibitors, CC214-1 and CC214-2, Preferentially Block the Growth of EGFRvIII-Activated Glioblastomas Open
PDF file - 5300K, CC214-1 synergizes at low doses with rapamycin. Quantification of the blots shown in Fig. 2B. PTEN detection on DEAL captured GBM39 cells upon CC214-1 treatment.
View article: Data from The mTOR Kinase Inhibitors, CC214-1 and CC214-2, Preferentially Block the Growth of EGFRvIII-Activated Glioblastomas
Data from The mTOR Kinase Inhibitors, CC214-1 and CC214-2, Preferentially Block the Growth of EGFRvIII-Activated Glioblastomas Open
Purpose: mTOR pathway hyperactivation occurs in approximately 90% of glioblastomas, but the allosteric mTOR inhibitor rapamycin has failed in the clinic. Here, we examine the efficacy of the newly discovered ATP-competitive mTOR kin…
View article: Supplementary Figure 4 from The mTOR Kinase Inhibitors, CC214-1 and CC214-2, Preferentially Block the Growth of EGFRvIII-Activated Glioblastomas
Supplementary Figure 4 from The mTOR Kinase Inhibitors, CC214-1 and CC214-2, Preferentially Block the Growth of EGFRvIII-Activated Glioblastomas Open
PDF file - 1694K, EGFRvIII expression sensitizes cells to CC214-1 mediated inhibition of proliferation and to autophagy.
View article: Supplementary Figure 7 from The mTOR Kinase Inhibitors, CC214-1 and CC214-2, Preferentially Block the Growth of EGFRvIII-Activated Glioblastomas
Supplementary Figure 7 from The mTOR Kinase Inhibitors, CC214-1 and CC214-2, Preferentially Block the Growth of EGFRvIII-Activated Glioblastomas Open
PDF file - 5321K, In vitro and in vivo pharmacological inhibition of autophagy sensitizes U87EGFRvIII cells and orthotopic xenografts to CC214-1/CC214-2 mediated apoptosis.
View article: Supplementary Figure 1 from The mTOR Kinase Inhibitors, CC214-1 and CC214-2, Preferentially Block the Growth of EGFRvIII-Activated Glioblastomas
Supplementary Figure 1 from The mTOR Kinase Inhibitors, CC214-1 and CC214-2, Preferentially Block the Growth of EGFRvIII-Activated Glioblastomas Open
PDF file - 3457K, Time course dependent CC214-1 treatment in a panel of isogenic GBM cell lines, U87EGFRvIII, U251 and LN229.
View article: Supplementary Figure 2 from The mTOR Kinase Inhibitors, CC214-1 and CC214-2, Preferentially Block the Growth of EGFRvIII-Activated Glioblastomas
Supplementary Figure 2 from The mTOR Kinase Inhibitors, CC214-1 and CC214-2, Preferentially Block the Growth of EGFRvIII-Activated Glioblastomas Open
PDF file - 5300K, CC214-1 synergizes at low doses with rapamycin. Quantification of the blots shown in Fig. 2B. PTEN detection on DEAL captured GBM39 cells upon CC214-1 treatment.
View article: Supplementary Figure 3 from The mTOR Kinase Inhibitors, CC214-1 and CC214-2, Preferentially Block the Growth of EGFRvIII-Activated Glioblastomas
Supplementary Figure 3 from The mTOR Kinase Inhibitors, CC214-1 and CC214-2, Preferentially Block the Growth of EGFRvIII-Activated Glioblastomas Open
PDF file - 1554K, Cap-dependent translation is enhanced by EGFRvIII expression and CC214-1 strongly inhibits P-4E-BP1 phosphorylation.
View article: Supplementary Figure 6 from The mTOR Kinase Inhibitors, CC214-1 and CC214-2, Preferentially Block the Growth of EGFRvIII-Activated Glioblastomas
Supplementary Figure 6 from The mTOR Kinase Inhibitors, CC214-1 and CC214-2, Preferentially Block the Growth of EGFRvIII-Activated Glioblastomas Open
PDF file - 2561K, Treatment with CC214-1, leads to induction of autophagy in GBM39 cells and genetic inhibition of autophagy sensitizes U87EGFRvIII cells to apoptosis.
View article: Supplementary Data from A First-in-Human Study of Novel Cereblon Modulator Avadomide (CC-122) in Advanced Malignancies
Supplementary Data from A First-in-Human Study of Novel Cereblon Modulator Avadomide (CC-122) in Advanced Malignancies Open
Supplementary Table S1. Summary of avadomide plasma pharmacokinetic parameters by day and dose level Supplementary Figure S1. Representative flow cytometry analysis of Aiolos degradation in peripheral B cells (A) and T cells (B). Supplemen…
View article: Data from The mTOR Kinase Inhibitors, CC214-1 and CC214-2, Preferentially Block the Growth of EGFRvIII-Activated Glioblastomas
Data from The mTOR Kinase Inhibitors, CC214-1 and CC214-2, Preferentially Block the Growth of EGFRvIII-Activated Glioblastomas Open
Purpose: mTOR pathway hyperactivation occurs in approximately 90% of glioblastomas, but the allosteric mTOR inhibitor rapamycin has failed in the clinic. Here, we examine the efficacy of the newly discovered ATP-competitive mTOR kin…